
==== Front
World J Diabetes
WJD
World Journal of Diabetes
1948-9358
Baishideng Publishing Group Inc

jWJD.v15.i9.pg1874
10.4239/wjd.v15.i9.1874
95797
Minireviews
Gut microbiome: A revolution in type II diabetes mellitus
Jeyaraman M et al. Gut microbiome and diabetes mellitus
Jeyaraman Madhan Department of Orthopaedics, ACS Medical College and Hospital, Dr MGR Educational and Research Institute, Chennai 600077, Tamil Nadu, India
Department of Orthopaedics, Brazilian Institute of Regenerative Medicine, Indaiatuba 13334-170, São Paulo, Brazil
Department of Orthopaedics, Orthopaedic Research Group, Coimbatore 641045, Tamil Nadu, India. madhanjeyaraman@gmail.com

Mariappan Tejaswin Department of Community Medicine, Government Stanley Medical College and Hospital, Chennai 600001, Tamil Nadu, India

Jeyaraman Naveen Department of Orthopaedics, ACS Medical College and Hospital, Dr MGR Educational and Research Institute, Chennai 600077, Tamil Nadu, India

Muthu Sathish Department of Orthopaedics, Orthopaedic Research Group, Coimbatore 641045, Tamil Nadu, India
Department of Orthopaedics, Government Medical College, Karur 639004, Tamil Nadu, India
Department of Biotechnology, Faculty of Engineering, Karpagam Academy of Higher Education, Coimbatore 641021, Tamil Nadu, India

Ramasubramanian Swaminathan Department of Orthopaedics, Government Medical College, Omandurar Government Estate, Chennai 600002, Tamil Nadu, India

Santos Gabriel Silva Department of Orthopaedics, Brazilian Institute of Regenerative Medicine, Indaiatuba 13334-170, São Paulo, Brazil

da Fonseca Lucas Furtado Department of Orthopaedics, Brazilian Institute of Regenerative Medicine, Indaiatuba 13334-170, São Paulo, Brazil

Lana José Fábio Department of Orthopaedics, Brazilian Institute of Regenerative Medicine, Indaiatuba 13334-170, São Paulo, Brazil

Author contributions: Jeyaraman M, Mariappan T, and Jeyaraman N contributed to conceptualization; Mariappan T and Ramasubramanian S contributed to acquiring clinical data and performing the data analysis; Jeyaraman M, Mariappan T, and Ramasubramanian S contributed to manuscript writing; Jeyaraman M, Santos GS, da Fonseca LF, and Lana JF helped in manuscript revision; Muthu S contributed to image acquisition; Jeyaraman M contributed to proofreading; Jeyaraman M and Lana JF contributed to administration; All authors have agreed to the final version to be published and agree to be accountable for all aspects of the work.

Corresponding author: Madhan Jeyaraman, MS, PhD, Assistant Professor, Research Associate, Department of Orthopaedics, ACS Medical College and Hospital, Dr MGR Educational and Research Institute, Velappanchavadi, Chennai 600077, Tamil Nadu, India. madhanjeyaraman@gmail.com

15 9 2024
15 9 2024
15 9 18741888
18 4 2024
11 6 2024
18 7 2024
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
Type II diabetes mellitus (T2DM) has experienced a dramatic increase globally across countries of various income levels over the past three decades. The persistent prevalence of T2DM is attributed to a complex interplay of genetic and environmental factors. While numerous pharmaceutical therapies have been developed, there remains an urgent need for innovative treatment approaches that offer effectiveness without significant adverse effects. In this context, the exploration of the gut microbiome presents a promising avenue. Research has increasingly shown that the gut microbiome of individuals with T2DM exhibits distinct differences compared to healthy individuals, suggesting its potential role in the disease’s pathogenesis and progression. This emerging field offers diverse applications, particularly in modifying the gut environment through the administration of prebiotics, probiotics, and fecal microbiome transfer. These inter-ventions aim to restore a healthy microbiome balance, which could potentially alleviate or even reverse the metabolic dysfunctions associated with T2DM. Although current results from clinical trials have not yet shown dramatic effects on diabetes management, the groundwork has been laid for deeper investigation. Ongoing and future clinical trials are critical to advancing our understanding of the microbiome’s impact on diabetes. By further elucidating the mechanisms through which microbiome alterations influence insulin resistance and glucose metabolism, researchers can develop more targeted interventions. The potential to harness the gut microbiome in developing new therapeutic strategies offers a compelling prospect to transform the treatment landscape of T2DM, potentially reducing the disease’s burden significantly with approaches that are less reliant on traditional pharmaceuticals and more focused on holistic, systemic health improvements.

Type II diabetes
Gut microbiome
Probiotics
Prebiotics
Fecal microbiota transplantation
==== Body
pmc Core Tip: Type II diabetes mellitus (T2DM) has surged globally, driven by genetic and environmental factors. Amidst pharmaceutical options, exploring the gut microbiome stands out. Research reveals distinct microbiome differences in T2DM, suggesting its role in pathogenesis. Interventions such as prebiotics, probiotics, and fecal transfers aim to restore balance. While clinical trials have not shown dramatic effects yet, ongoing research holds promise. Understanding microbiome mechanisms could revolutionize T2DM treatment, emphasizing holistic health approaches.

INTRODUCTION

The human gut microbiome is a complex ecosystem, hosting thousands of bacterial species, each exerting a unique influence on host metabolism. This intricate interplay involves a variety of signaling molecules derived from dietary components that are metabolized by these microbiota. The role of the gut microbiome extends beyond digestion, as it actively engages with multiple bodily systems to maintain physiological homeostasis[1]. In the context of type II diabetes mellitus (T2DM), the gut microbiome exhibits notable changes, termed dysbiosis, where there is an increase in bacteria that negatively impact metabolic health and a decrease in beneficial bacteria[2,3]. This shift can lead to a cascade of health issues, including metabolic disorders, cardiovascular complications, neuronal diseases, and various inflammatory conditions, as depicted in Figure 1[4,5].

Figure 1 Communication channels of the gut with various systems of the body through metabolites produced by the gut microbiota. LPS: Lipopolysaccharides; SCFAs: Short-chain fatty acids.

Despite understanding the broad impacts of gut microbiome dysbiosis, specific pathways, and interactions that lead to T2DM remain underexplored. The mechanisms through which microbial products and toxins contribute to increased intestinal permeability and subsequent inflammation are not fully elucidated. Furthermore, the exact nature of changes in the production of short-chain fatty acids (SCFAs), lipopolysaccharides, and bile acids in diabetics requires detailed investigation[6-8]. These gaps in knowledge hinder the full exploitation of the gut microbiome as a target for therapeutic interventions. Understanding these pathways in greater depth could unveil novel strategies to manage or potentially reverse the effects of dysbiosis in diabetic patients. The primary objective of this review is to synthesize current understandings of the microbiome’s role in T2DM, with a particular focus on the pathophysiological changes associated with dysbiosis. We aimed to identify and discuss novel therapeutic strategies that target the microbiome to ameliorate the symptoms and complications associated with T2DM.

GUT MICROBIOTA AND ITS EFFECTS ON T2DM

Organisms with a positive correlation with the disease

The microbiome composition in individuals with diabetes, particularly T2DM, exhibits significant variations compared to non-diabetic individuals. Notably, the phyla Proteobacteria and Firmicutes[3] are predominantly observed in diabetics. Within Firmicutes, there is a noted increase in the genus Ruminococcus and a decrease in Clostridium species[3], as demonstrated in Figure 2, which outlines the microbiota profile variation in T2DM. However, observations in patients of different ethnicities may vary and needs further investigation.

Figure 2 Microbiota profile variation in type II diabetes mellitus. DM: Diabetes mellitus.

Research highlights that the Firmicutes-to-Bacteroides ratio, which is typically below 0.8 in healthy individuals, is elevated in those with T2DM and obesity. This altered ratio is indicative of microbial dysbiosis associated with these conditions[9-11]. Using a Predomics approach, three species have been identified as significant biomarkers for T2DM: Enterococcus faecium, Eubacterium linosum, and Absiella spp.[12]. Eubacterium linosum, an anaerobic acetogenic bacterium, is particularly noteworthy for its metabolic functions, including acetate production, sulfate reduction, and the degradation of urea and arginine. These metabolic activities contribute to chronic low-grade inflammation via pro-inflammatory cytokines and metabolites, a hallmark of T2DM[13,14]. Additionally, the production of acetate through the fermentation of galacto-oligosaccharides or inulin is linked to alterations in insulin sensitivity and weight gain[8,15]. Certain species within the Firmicutes phylum are recognized for their enhanced capacity to break down complex sugars and fatty acids, thereby potentially increasing the risk of obesity and T2DM[16]. On the other hand, some species within the Proteobacteria phylum, such as Fusobacterium spp., are implicated in protein fermentation and degradation, leading to dysbiosis. Fusobacterium spp. also contributes to pathogenicity by inducing inflammatory cytokines [interleukin (IL)-1β, tumor necrosis factor (TNF)-α, IL-17, etc.], which further exacerbate the inflammatory state[17,18].

Organisms with a negative correlation with the disease

Several organisms exhibit a negative correlation with T2DM, primarily through mechanisms that involve the production of anti-inflammatory and immunoregulatory metabolites such as butyrate and propionate[14]. Among these, the genus Bifidobacterium is notably protective against T2DM, attributed to its cross-feeding mechanisms that enhance metabolic health[19]. Animal studies further corroborate the benefits of various species within this genus, demonstrating an increase in glucose tolerance[20-24].

Another significant genus negatively correlated with T2DM is Bacteroides. This group, which includes species like Bacteroides uniformis and Bacteroides acidifaciens, is known to improve glucose tolerance and insulin sensitivity, and is instrumental in managing metabolic diseases exacerbated by poor diet[25,26]. Despite their reduced presence in individuals with T2DM, other genera such as Faecalibacterium, Akkermansia, and Roseburia also exhibit similar negative correlations with the disease, though they are not as abundantly reported[27]. Lactobacillus species display variable associations with T2DM; however, species like Lactobacillus plantarum[28], Lactobacillus casei[29], and Lactobacillus reuteri[30] have been shown to improve symptoms when administered as probiotics. In synergy with Bifidobacterium, they confer a collective protective effect against the disease[31-37]. SCFAs such as butyrate play crucial roles beyond their metabolic functions; they regulate pancreatic beta-cell activity, reduce hepatic gluconeogenesis, and modulate immune system functions. The reduction in these critical microbiota directly contributes to the pathogenesis of T2DM.

Gut metabolites

The fermentation of nutrients by gut microbiota leads to the production of metabolites like SCFAs (butyrate, propionate, acetate), branched-chain amino acids, indoles, imidazoles, and succinates. These are predominantly produced by genera including Bacteroides, Akkermansia, Prevotella, Faecalibacterium, Lactobacillus, Clostridium, and Propionibacterium. These metabolites have diverse and significant interactions within the gut environment, as illustrated in Figure 3.

Figure 3 Metabolite breakdown products of gut microbiome. GLP-1: Glucagon-like peptide-1.

Pathogenesis of dysbiosis contributing to worsening T2DM

Alteration in permeability and steatosis: Changes in the gut microbiome composition have been associated with T2DM progression, particularly a decrease in species such as Bacteroides and Akkermansia. These microbes are crucial for the regulation of tight junction proteins including occludin and claudin, which maintain intestinal barrier integrity[4,38]. The disruption of these tight junctions leads to increased intestinal permeability. This, in turn, facilitates enhanced nutrient absorption and altered glycemic control, propelling the progression toward steatosis. Concurrently, the reduction in microbial populations that regulate hepatic gluconeogenesis exacerbates liver steatosis.

Inflammation and altered lipopolysaccharides: Increased intestinal permeability allows greater absorption of dietary products and bacterial endotoxins, such as lipopolysaccharides, into the bloodstream. This elevates the production of pro-inflammatory cytokines, including TNF-α, IL-1β, IL-6, IL-17, and other cytokines linked to T helper (Th)1, Th2, and Th17 responses. This state of endotoxemia drives systemic inflammation and reactive oxygen species production, leading to the destruction of pancreatic beta cells and the onset of insulin resistance[4,38]. The absence of protective microbial effects due to altered microbiota composition, such as those from Roseburia intestinalis, Bacteroides fragilis, Akkermansia spp., and Lactobacillus casei, further compounds the problem. These species induce anti-inflammatory cytokines like IL-10, which may help mitigate low-grade inflammation and potentially improve insulin sensitivity. Roseburia intestinalis, for example, also promotes the production of IL-22, enhancing insulin sensitivity, and transforming growth factor-beta, inhibiting inflammatory processes.

Fatty acid metabolism: The altered composition of gut flora observed in T2DM patients may affect the production of SCFAs. These SCFAs, such as butyrate and propionate, are essential in promoting fatty acid oxidation by inhibiting the expression of peroxisome proliferator-activated receptor-gamma[39]. The absence of these regulatory mechanisms is evident in conditions like increased serum malonaldehyde, a marker for lipid oxidation, which is typically reduced by Lactobacillus casei and Akkermansia muciniphila in experimental models, but is elevated in diabetic subjects[40,41]. This disruption leads to enhanced fat accumulation in adipose tissue and the liver[42-44], triggering a modification in bile acid metabolism. Such alterations further propagate inflammation and microbial imbalance, perpetuating a cyclical exacerbation of T2DM pathogenesis[4]. Having discussed the potential associations between gut metabolites from microbiome dysbiosis and T2DM progression, specific targets to ameliorate their impact remains an area of future research.

Changes of the gut microbiome at different stages/complications of T2DM

The changes in the gut microbiome studied through various human and animal studies, a targeted replenishment of gut microbiota, can lead to delay or prevention in complications of diabetes through supplementation by probiotics, prebiotics, and fecal microbial transplantation, which in turn restores the stability of gut microbiota, as mentioned in Table 1.

Table 1 Dysbiosis observed in various stages of diabetes mellitus

Complication/stage observed	Dysbiosis observed	
Decreased	Increased	
Diabetic nephropathy	Lactobacillus, Bifidobacterium, Bacteroides, Prevotella, Roseburia, Ruminococcaceae, and Faecalibacterium	Enterococcus, Enterobacteriaceae, Clostridaceae, Klebsiella, and Parabacterides	
Diabetic neuropathy	Bacteroides and Faecalibacterium	Escherichia, Blautia, Ruminococcus torques, and Lachnoclostridium	
Diabetic retinopathy	Bacteroidetes and Actinobacteria	Escherihia, Enterobacter, and Acidaminococcus	
Cerebrovascular disease	Lachnospiraceae, Ruminococcaceae, Bacteroidetes, Prevotella, and Faecalibacterium	Enterobacteriaceae, Veillonellaceae, Bifidobacterium, Lactobacillus, and Oscillobacter	
Cardiovascular disease	Roseburia, Eubacterium spp, Bacteroides and Faecalibacterium	Collinsella, Escherichia-Shigella, Enterococcus, and the ratio of Firmicutes to Bacteroides	
Peripheral vascular disease	-	Firmicutes, Actinobacteria, Verrucomicrobia, and Proteobacteria	

Effects of diabetic medications on the gut microbiome

Metformin: Metformin is well-documented for its favorable modifications to the gut microbiome. According to Ismail and Evans-Molina[45], metformin treatment leads to changes in the composition of gut microbiota, enhancing the production of SCFAs and altering bile acids. These changes result in increased levels of glucagon-like peptide-1 (GLP-1), which promotes insulin secretion. Additionally, metformin helps normalize the altered microbial community by reversing the Firmicutes/Bacteroides ratio, which is often disrupted in diabetic conditions, thus restoring the microbiome toward a healthier state[4].

Sulfonylureas: The effects of sulfonylureas on the gut microbiome are less clear, with studies presenting conflicting data. One study reports that the use of sulfonylureas is associated with increased levels of phenylalanine and tryptophan, suggesting a potential impact on the microbiome[46]. However, another study found no significant changes in the composition of the gut microbiota with sulfonylurea treatment[47]. This indicates that the influence of sulfonylureas on the gut microbiome may vary depending on other factors such as dosage, duration of treatment, and individual patient microbiome composition.

Alpha-glucosidase inhibitors: Alpha-glucosidase inhibitors prevent the breakdown of oligosaccharides in the small intestine, thereby increasing their availability as nutrients for gut bacteria. This alteration in nutrient availability promotes the growth of beneficial microbes such as Bacteroides, Lactobacillus, and Faecalibacterium, while reducing populations of potentially pathogenic bacteria like Ruminococcus and Butyricicoccus[48]. These microbial shifts are associated with changes in bile acid profiles and improvements in prognostic factors for T2DM.

GLP-1 agonists: GLP-1 agonists, which slow gastric emptying, induce significant shifts in the gut microbial community. Studies indicate a reduction in obesity-promoting organisms within the Firmicutes phylum and an increase in po-pulations of Verrucomicrobia and microbes from the orders Clostridiales and Bacteroidales[49]. These drugs also promote the growth of SCFA-producing bacteria such as Bifidobacterium and Bacteroides, further supporting glycemic control and metabolic health[50].

Sodium-glucose co-transporter type 2 inhibitors: Sodium-glucose co-transporter type 2 inhibitors, such as sotagliflozin, impact the gut microbiome by decreasing the Firmicutes/Bacteroides ratio and enhancing fatty acid production[51]. This alteration not only affects the microbial landscape but also has broader implications for energy metabolism and insulin sensitivity in T2DM patients. A summary of the effects of diabetic medications on the gut microbiome is tabulated in Table 2.

Table 2 Effects of diabetic medications on gut microbiome

Medication	Effects on microbiome	Observed outcomes	
Metformin[45]	Enhances SCFA production, normalizes Firmicutes/Bacteroides ratio	Increased GLP-1 levels, improved insulin secretion	
Sulfonylureas[46,47]	Conflicting data on impact	Variable influence on microbiome, potential increase in phenylalanine and tryptophan levels	
Alpha-glucosidase inhibitors[48]	Increases nutrient availability for beneficial bacteria	Growth of beneficial microbes like Bacteroides, improvement in T2DM prognostic factors	
GLP-1 agonists[49,50]	Changes in gastric emptying rates influence microbiota	Reduction in obesity-promoting organisms, increase in beneficial microbes like Bifidobacterium	
SGLT-2 inhibitors[51]	Alters microbial ratios favorably	Reduction in Firmicutes/Bacteroides ratio, enhanced fatty acid production	
DM: Diabetes mellitus; GLP-1: Glucagon-like peptide-1; SCFA: Short-chain fatty acid; SGLT-2: Sodium-glucose co-transporter type 2.

Influence of diet and exercise on gut microbiome

The influence of diet and exercise on the gut microbiome has significant implications for the management of conditions such as T2DM. Various dietary patterns and physical activities have been shown to differentially affect the composition and functionality of the gut microbiota, with direct consequences on metabolic health (Table 3).

Table 3 Impact of diet and exercise on the gut microbiome in type 2 diabetes mellitus

Factor	Description	Beneficial effects	
Diet	High fiber plant-based foods[4,52]	Decrease in insulin resistance, stabilization of blood glucose levels, reduction in serum cholesterol	
High-fat and protein diets[53]	Increase in pro-inflammatory markers; variable effects based on protein source (plant vs animal)	
Mediterranean diet[54]	Improvement in SCFA production, enhanced insulin sensitivity, increased beneficial genera like Roseburia	
Exercise	Low-intensity physical activity[55-57]	Favorable shifts in microbiota composition, improvement in metabolic health markers	
SCFA: Short-chain fatty acid.

Dietary influences

A diet rich in plant-based fibers such as cellulose, inulin, pectin, and dextrin has been found to confer multiple health benefits, including reduced insulin resistance, lower serum cholesterol levels, and stable blood glucose levels. These effects are largely attributed to the enrichment of beneficial gut bacteria that negatively correlate with metabolic diseases. These bacteria produce SCFAs such as butyrates and propionates, which play a crucial role in reducing the production of pro-inflammatory cytokines, thereby mitigating inflammation associated with T2DM[4,52]. Conversely, diets high in fats and proteins, particularly from animal sources, tend to foster a pro-inflammatory gut environment. This is largely due to an increase in lipopolysaccharides, which are potent inflammatory agents. However, it is important to note that not all protein-rich diets have adverse effects. Diets rich in plant proteins can enhance the proliferation of beneficial microbes such as Lactobacillus spp. and Bifidobacterium spp. In contrast, diets high in animal proteins tend to increase levels of Bacteroides and Bilophila, which have mixed effects on health depending on the overall dietary context[53]. The Mediterranean diet, which is rich in vegetables, fruits, nuts, seeds, and whole grains, has been specifically noted for its positive alterations to the gut microbiota. Adherence to this diet enhances the production of SCFAs, thereby improving insulin sensitivity. Observational studies in obese patients have shown increases in beneficial genera such as Roseburia and Oscillospira, alongside a reduction in Prevotella spp., which are associated with dysbiosis and metabolic disturbances. The beneficial shifts in the gut microbiome are contingent upon strict adherence to the dietary regimen[54].

Exercise influence

Physical exercise also plays a critical role in modulating the gut microbiome. Low-intensity physical activities have been associated with favorable changes in the gut microbiota composition, including an increase in the Bacteroides/Firmicutes ratio[55-57]. This shift helps mitigate the adverse effects of an unhealthy diet and contributes to overall metabolic health. Exercise-induced modifications to the microbiome can enhance the resilience of the gut ecosystem, promoting a balance that favors metabolic health and potentially reducing the risk or severity of T2DM.

THERAPIES FOR T2DM BASED ON THE GUT MICROBIOME

Nutraceutical agents

Lactobacillus and Bifidobacterium are among the most extensively studied probiotics, known for their beneficial effects on glycemic control. Meta-analyses have demonstrated that supplementation with these microbes can significantly decrease hemoglobin A1c, fasting blood glucose, and markers of oxidative stress[58]. Additionally, the introduction of Akkermansia muciniphila, a recent focus in microbiome research, has shown promising results. In murine models, this bacterium has been found to increase GLP-1 levels in colon cells, enhance glucose tolerance, and maintain gut barrier integrity, thereby reducing inflammation and ameliorating liver damage[59]. Research indicates that Akkermansia muciniphila also modulates the Firmicutes/Bacteroides ratio, leading to increased butyrate production. These changes collectively contribute to reduced oxidative stress and improved lipid profiles and glucose tolerance[39].

Fecal microbiota transplantation

Beyond probiotics, fecal microbiota transplantation (FMT) represents a more direct method for altering the gut microbiome. Initially popularized through its efficacy in treating Clostridium difficile infections, which often arise from chronic antibiotic use and the resultant suppression of native flora, FMT has since broadened its clinical applications[60]. Data from various human studies suggest that FMT can decrease inflammatory markers and increase the production of secondary bile acids, although its effects on insulin resistance have been relatively mild[61]. This indicates that, while FMT holds potential, its full spectrum of therapeutic benefits in T2DM remains to be fully elucidated through additional clinical trials. Despite its potential, FMT carries risks, particularly the possibility of transferring a dysbiotic microbiome and infectious pathogens. Therefore, while FMT is a promising tool in the arsenal against metabolic diseases, its application must be approached with caution, ensuring rigorous screening and monitoring protocols to mitigate these risks. A summary of evidence of the role of the gut microbiome in T2DM is tabulated in Table 4.

Table 4 Summary of global studies of the gut microbiome in type 2 diabetes mellitus

Ref.	Place of study	Probiotics used	Observed effects	
Kumari et al[62], 2021	India	Lactobacillus spp.	Decreased HbA1C, insulin resistance, TNF-α, IL-1β	
Lactococcus spp.	
Propionibacterium spp.	
Bifidobacterium spp.	
Zhao et al[63], 2020	China	Selenium enhanced	Decreased FG, HbA1C, and insulin levels and improves glucose tolerance and lipid profile	
Bifidobacterium spp.	
Palacios et al[64], 2020	Australia	Lactobacillus plantarum	Decreased FG, HbA1C, and insulin resistance	
Lactobacillus bulgaricus	
Lactobacillus gasseri	
Bifidobacterium breve	
Bifidobacterium animalis sbsp. lactis	
Bifidobacterium bifidum	
S. thermophiles	
S. boulardii	
Razmpoosh et al[65], 2019	Iran	Lactobacillus acidophilus	Decreased FG, insulin resistance, and increased HDL cholesterol	
Lactobacillus casei	
Lactobacillus rhamnosus	
Lactobacillus bulgaricus	
Bifidobacterium breve	
Bifidobacterium longum	
Streptococcus thermophilus	
Madempudi et al[66], 2019	India	Lactobacillus salivarius	Decreased HbA1C and effects on lipid profile are not significant	
Lactobacillus casei	
Lactobacillus plantarum	
Lactobacillus acidophilus	
Bifidobacterium breve	
Bifidobacterium coagulans	
Sabico et al[67], 2019	Saudi Arabia	Bifidobacterium bifidum W23	Decreased FG, insulin resistance, total cholesterol, and triglycerides	
Bifidobacterium lactis W52	
Lactobacillus acidophilus W37	
Lactobacillus brevis W63	
Lactobacillus casei W56	
Lactobacillus salivarius W24	
Lactobacillus lactis W19	
Lactobacillus lacis W58	
Mazruei Arani et al[68], 2019	Iran	Bacillus coagulans T4	Decreased FG, insulin resistance, CRP, and improves lipid profile	
Mohseni et al[37], 2018	Iran	Lactobacillus acidophilus	Decreased FG, insulin resistance, inflammatory markers, and improves lipid profile	
Bifidobacterium bifidum	
Lactobacillus casei	
Lactobacillus fementum	
Kobyliak et al[61], 2018	Ukraine	14 probiotic strains of Lactobacillus	Decreased HbA1C and insulin resistance	
Lactococcus	
Bifidobacterium spp.	
Propionibacterium	
Acetobacter	
Kassaian et al[69], 2018	Iran	Lactobacillus acidophilus	Decreased FG, HbA1C, and insulin resistance	
Bifidobacterium lactis	
Bifidobacterium bifidum	
Bifidobacterium longum	
Mohseni et al[37], 2018	Iran	Bifidobacterium bifidum	Decrease FG, insulin resistance, total cholesterol, and increased GSH level	
Lactobacillus casei	
Lactobacillus acidophilus	
Mofidi et al[35], 2017	Iran	Lactobacillus casei	Decreased FG and triglycerides	
Lactobacillus rhamnosus	
Streptococcus thermophilus	
Bifidobacterium breve	
Lactobacillus acidophilus	
Bifidobacterium longum	
Lactobacillus bulgaricus	
Firouzi et al[36], 2017	Malaysia	Lactobacillus acidophilus	Decreased HbA1C and does not affect lipid profile	
Lactobacillus casei	
Lactobacillus lactis	
Bifidobacterium bifidum	
Bifidobacterium longum	
Bifidobacterium infantis	
Tajabadi-Ebrahimi et al[33], 2017	Iran	Lactobacillus acidophilus	Decreased FG, increased insulin sensitivity, and does not affect lipid profile	
Lactobacillus casei	
Bifidobacterium bifidum	
Ebrahimi et al[70], 2017	Iran	Lactobacillus spp.	Decreased FG, HbA1C, and no effect on lipid profile	
Bifidobacterium spp.	
Streptococcus thermophilus and fructo-oligosaccharide	
Asemi et al[71], 2016	Iran	Probiotic: Lactobacillus sporogenes	Decreased in serum insulin, insulin resistance, triglycerides and increased GSH levels	
Prebiotic: Inulin, beta-carotene	
Madjd et al[72], 2016	Iran	Lactobacillus acidophilus LA5	Decreased HbA1C, 2-h postprandial glucose, insulin resistance, total cholesterol, and LDL levels	
Bifidobacterium lactis BB12	
Karamali et al[73], 2016	Iran	Lactobacillus acidophilus	Decreased fasting glucose, insulin resistance, triglycerides, VLDL, and increased insulin sensitivity	
Lactobacillus casei	
Bifidobacterium bifidum	
Ostadrahimi et al[74], 2015	Iran	Lactobacillus acidophilus	Decreased HbA1C, and FG and does not affect lipid profile	
Lactobacillus casei	
Bifidobacterium lactis	
Eslamparast et al[75], 2014	Iran	Lactobacillus casei	Decreased FG, insulin resistance and has no effect on lipid profile	
Lactobacillus rhamnosus	
Streptococcus thermophilus	
Bifidobacterium breve	
Lactobacillus acidophilus	
Bifidobacterium longum	
Lactobacillus bulgaricus	
Rajkumar et al[76], 2014	India	Bifidobacterium longum	Decreased FG, insulin resistance, total cholesterol, triglycerides, LDL, VLDL, and increased HDL levels	
Bifidobacterium infantis	
Bifidobacterium breve	
Lactobacillus acidophilus	
Lactobacillus paracasei	
Lactobacillus bulgaricus	
Lactobacillus plantarum	
Streptococcus thermophilus	
Ivey et al[77], 2014	Australia	Lactobacillus acidophilus La5	Increased FG and insulin resistance	
Bifidobacterium lactis Bb12	
Mohamadshahi et al[78], 2014	Iran	Bifidobacterium lactis Bb12	Decreased HbA1C	
Lactobacillus acidophilus	
Asemi et al[79], 2014	Iran	Probiotic: Viable & heat-resistant Lactobacillus sporogenes	Decreased FG, HbA1C, insulin resistance, and inflammatory markers	
Prebiotic: Inulin	
Asemi et al[34], 2013	Iran	Lactobacillus spp.	Decreased FG and increased insulin levels, total GSH levels, and LDL levels	
Bifidobacterium spp.	
Streptococcus spp.
Fructo-oligosaccharide	
Mazloom et al[80], 2013	Iran	Lactobacillus acidophilus	Decreased FG, insulin resistance, and improves fasting insulin	
Lactobacillus bulgaricus	
Lactobacillus bifidum	
Lactobacillus casei	
Shavakhi et al[81], 2013	Iran	Lactobacillus acidophilus	Decreased FG, triglycerides, and total cholesterol	
Lactobacillus casei	
Lactobacillus rhamnosus	
Lactobacillus bulgaricus	
Bifidobacterium breve	
Bifidobacterium longum	
Streptococcus thermophilus	
Asemi et al[82], 2013	Iran	Lactobacillus acidophilus LA5	Decreased insulin resistance	
Bifidobacterium animalis BB12	
Asemi et al[34], 2013	Iran	Lactobacillus acidophilus	Decreased FG, increased insulin resistance, and LDL levels	
Lactobacillus casei	
Lactobacillus rhamnosus	
Lactobacillus bulgaricus	
Bifidobacterium breve	
Bifidobacterium longum	
Streptococcus thermophiles	
Moroti et al[31], 2012	Brazil	Lactobacillus acidophilus	Decreased FG and increased HDL levels	
Bifidobacterium bifidum	
Ejtahed et al[83], 2012	Iran	Lactobacillus acidophilus La5	Decreased FG and HbA1C and does not affect lipid profile	
Bifidobacterium lactis Bb12	
Laitinen et al[84], 2009	Finland	Lactobacillus rhamnosus GG	Decreased FG, insulin resistance, and increased insulin sensitivity	
Bifidobacterium lactis Bb12	
CRP: C-reactive protein; FG: Fasting glucose; GSH: Glutathione; HbA1C: Hemoglobin A1c; HDL: High-density lipoprotein; IL: Interleukin; LDL: Low-density lipoprotein; TNF: Tumor necrosis factor; VLDL: Very low-density lipoprotein.

Challenges and limitations

One of the principal challenges in leveraging the gut microbiome for diabetes treatment is the inherent variability in microbial composition among individuals. Factors such as genetics, diet, age, and environment significantly influence the gut microbiota, creating a highly personalized microbial ecosystem. This variability can affect the efficacy of probiotic treatments, as the same probiotic strains may not produce identical effects in different individuals. The lack of standardization in probiotic formulations poses another significant challenge. Probiotics are available in various forms, from dietary supplements to fortified foods, with considerable differences in strain specificity, viability, and concentration. These discrepancies can lead to inconsistent study results and confusion about their clinical applicability. Moreover, the regulation of probiotics varies by region, affecting the quality and safety of available products.

While short-term studies have demonstrated the potential benefits of probiotics in managing T2DM, long-term safety and efficacy remain underexplored. Questions about the optimal duration of probiotic therapy, long-term side effects, and the sustainability of beneficial effects need to be addressed through longitudinal studies. A deeper mechanistic understanding of how probiotics interact with both the gut microbiota and the host is crucial. Current knowledge about the pathways through which probiotics influence metabolic health, including their effects on inflammation, insulin sensitivity, and lipid metabolism, is still rudimentary. Enhanced mechanistic insights would facilitate the development of more targeted and effective therapeutic strategies. Interactions between probiotics and other medications commonly used by diabetic patients pose another layer of complexity. The potential for probiotics to affect drug metabolism and efficacy needs thorough investigation to avoid adverse effects and ensure complementary therapeutic outcomes.

Future directions

Advancing a personalized medicine approach in microbiome research could significantly enhance the efficacy of treatments. By understanding individual microbiome profiles, treatments can be tailored to optimize microbial composition and functionality. This approach would involve integrating detailed genomic, metabolic, and dietary data to predict individual responses to specific probiotic strains. Research into next-generation probiotics, which are specifically engineered or selected based on their beneficial characteristics, is a promising direction. These could include not only bacteria but also other components of the microbiota such as beneficial viruses or fungi that play a role in metabolic regulation.

Combining probiotics with other therapeutic modalities, such as dietary interventions, pharmacotherapy, and lifestyle changes, could enhance overall treatment outcomes. For example, synchronizing probiotic supplementation with a fiber-rich diet might amplify the beneficial effects on the gut microbiome. Conducting more rigorous and comprehensive clinical trials that focus on various demographic groups and different stages of diabetes is crucial. These studies should aim to clarify optimal dosages, treatment durations, and combinations of probiotic strains. Moreover, trials should also assess the impact of probiotics on diabetes complications, offering a broader understanding of their potential benefits. Enhancing healthcare provider and patient education about the potential benefits and limitations of probiotics as part of diabetes management is essential. Increased awareness can lead to more informed decision-making and better clinical outcomes. The limitations and future directions in gut microbiome research for T2DM are summarized in Table 5.

Table 5 Limitations and future directions in gut microbiome research for type 2 diabetes mellitus

Limitations	Description	Future directions	
Variability in microbial composition	Individual differences in microbiome composition complicate standard treatment outcomes	Personalized microbiome interventions: Develop treatments based on individual microbiome assessments to optimize efficacy	
Lack of standardization	Inconsistencies in probiotic formulations affect study comparability and clinical applicability	Standardization of products: Establish regulations and standards for probiotic formulations to ensure quality and consistency	
Short-term focus	Most studies have short duration and do not address long-term safety and effectiveness	Longitudinal studies: Conduct long-term studies to assess the sustained effects and safety of microbiome-based interventions	
Incomplete mechanistic understanding	The pathways through which the microbiome influences diabetes are not fully elucidated	Mechanistic research: Deepen research into the biochemical interactions within the gut microbiome that affect diabetes pathogenesis and treatment	
Drug-microbiome interactions	Potential interactions between probiotics and anti-diabetic medications are not well understood	Interaction studies: Explore how probiotics interact with common diabetic medications to refine treatment protocols	
Regulatory hurdles	The global regulatory landscape for probiotics and microbiome therapies varies significantly	Harmonize regulations: Work toward an international consensus on the regulation of microbiome therapies to facilitate global research and application	

CONCLUSION

T2DM significantly impacts the gut microbiota, leading to dysbiosis, which in turn promotes inflammation and contributes to the development of insulin resistance. The evidence gathered from various trials and studies underscores the pivotal role of nutraceuticals in restoring a balanced gut flora, enhancing insulin sensitivity, and reducing insulin resistance. These beneficial effects have been consistently observed in animal models and, to a lesser extent, in human studies. Although the initial outcomes from human trials have not met all expectations, they lay a solid foundation for future research. Continued exploration and more targeted studies are essential to refine these interventions and fully assess their therapeutic potential. With ongoing advancements and deeper insights into gut microbiome interactions, nutraceuticals hold promise as a novel and effective treatment strategy to manage T2DM. As research progresses, these natural compounds will become an integral part of comprehensive diabetes management, potentially shifting current therapeutic paradigms.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Endocrinology and metabolism

Country of origin: India

Peer-review report’s classification

Scientific Quality: Grade B, Grade C, Grade C, Grade C, Grade D

Novelty: Grade B, Grade C, Grade C

Creativity or Innovation: Grade B, Grade C, Grade C

Scientific Significance: Grade B, Grade B, Grade C

P-Reviewer: Bortolotti M; Han J; Horowitz M; Lie Z; Papazafiropoulou A S-Editor: Wang JJ L-Editor: Filipodia P-Editor: Chen YX
==== Refs
1 Wang B Yao M Lv L Ling Z Li L The Human Microbiota in Health and Disease Engineering 2017 3 71 82
2 Barlow GM Mathur R Type 2 Diabetes and the Microbiome J Endocr Soc 2022 7 bvac184 36578879
3 Dash NR Al Bataineh MT Alili R Al Safar H Alkhayyal N Prifti E Zucker JD Belda E Clément K Functional alterations and predictive capacity of gut microbiome in type 2 diabetes Sci Rep 2023 13 22386 38104165
4 Sadagopan A Mahmoud A Begg M Tarhuni M Fotso M Gonzalez NA Sanivarapu RR Osman U Latha Kumar A Mohammed L Understanding the Role of the Gut Microbiome in Diabetes and Therapeutics Targeting Leaky Gut: A Systematic Review Cureus 2023 15 e41559 37554593
5 Iatcu CO Steen A Covasa M Gut Microbiota and Complications of Type-2 Diabetes Nutrients 2021 14
6 Zhang D Jian YP Zhang YN Li Y Gu LT Sun HH Liu MD Zhou HL Wang YS Xu ZX Short-chain fatty acids in diseases Cell Commun Signal 2023 21 212 37596634
7 Birkeland E Gharagozlian S Valeur J Aas AM Short-chain fatty acids as a link between diet and cardiometabolic risk: a narrative review Lipids Health Dis 2023 22 40 36915164
8 Hernández MAG Canfora EE Jocken JWE Blaak EE The Short-Chain Fatty Acid Acetate in Body Weight Control and Insulin Sensitivity Nutrients 2019 11
9 Santos VM Brito AKP Amorim AT Souza IR Santos MB Campos GB Dos Santos DC Júnior ACRB Santana JM Santos DB Mancini MC Timenetsky J Marques LM Evaluation of fecal microbiota and its correlation with inflammatory, hormonal, and nutritional profiles in women Braz J Microbiol 2022 53 1001 1009 35277849
10 Magne F Gotteland M Gauthier L Zazueta A Pesoa S Navarrete P Balamurugan R The Firmicutes/Bacteroidetes Ratio: A Relevant Marker of Gut Dysbiosis in Obese Patients? Nutrients 2020 12
11 Stojanov S Berlec A Štrukelj B The Influence of Probiotics on the Firmicutes/Bacteroidetes Ratio in the Treatment of Obesity and Inflammatory Bowel disease Microorganisms 2020 8
12 Kolmeder CA de Vos WM Roadmap to functional characterization of the human intestinal microbiota in its interaction with the host J Pharm Biomed Anal 2021 194 113751 33328144
13 Hughes ER Winter MG Duerkop BA Spiga L Furtado de Carvalho T Zhu W Gillis CC Büttner L Smoot MP Behrendt CL Cherry S Santos RL Hooper LV Winter SE Microbial Respiration and Formate Oxidation as Metabolic Signatures of Inflammation-Associated Dysbiosis Cell Host Microbe 2017 21 208 219 28182951
14 Crudele L Gadaleta RM Cariello M Moschetta A Gut microbiota in the pathogenesis and therapeutic approaches of diabetes EBioMedicine 2023 97 104821 37804567
15 Wong JM de Souza R Kendall CW Emam A Jenkins DJ Colonic health: fermentation and short chain fatty acids J Clin Gastroenterol 2006 40 235 243 16633129
16 Binda C Gibiino G Coluccio C Sbrancia M Dajti E Sinagra E Capurso G Sambri V Cucchetti A Ercolani G Fabbri C Biliary Diseases from the Microbiome Perspective: How Microorganisms Could Change the Approach to Benign and Malignant Diseases Microorganisms 2022 10
17 Yang Y Weng W Peng J Hong L Yang L Toiyama Y Gao R Liu M Yin M Pan C Li H Guo B Zhu Q Wei Q Moyer MP Wang P Cai S Goel A Qin H Ma Y Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-κB, and Up-regulating Expression of MicroRNA-21 Gastroenterology 2017 152 851 866.e24 27876571
18 Hall AB Yassour M Sauk J Garner A Jiang X Arthur T Lagoudas GK Vatanen T Fornelos N Wilson R Bertha M Cohen M Garber J Khalili H Gevers D Ananthakrishnan AN Kugathasan S Lander ES Blainey P Vlamakis H Xavier RJ Huttenhower C A novel Ruminococcus gnavus clade enriched in inflammatory bowel disease patients Genome Med 2017 9 103 29183332
19 Falony G Vlachou A Verbrugghe K De Vuyst L Cross-feeding between Bifidobacterium longum BB536 and acetate-converting, butyrate-producing colon bacteria during growth on oligofructose Appl Environ Microbiol 2006 72 7835 7841 17056678
20 Rowland I Gibson G Heinken A Scott K Swann J Thiele I Tuohy K Gut microbiota functions: metabolism of nutrients and other food components Eur J Nutr 2018 57 1 24
21 Le TK Hosaka T Nguyen TT Kassu A Dang TO Tran HB Pham TP Tran QB Le TH Pham XD Bifidobacterium species lower serum glucose, increase expressions of insulin signaling proteins, and improve adipokine profile in diabetic mice Biomed Res 2015 36 63 70 25749152
22 Moya-Pérez A Neef A Sanz Y Bifidobacterium pseudocatenulatum CECT 7765 Reduces Obesity-Associated Inflammation by Restoring the Lymphocyte-Macrophage Balance and Gut Microbiota Structure in High-Fat Diet-Fed Mice PLoS One 2015 10 e0126976 26161548
23 Kikuchi K Ben Othman M Sakamoto K Sterilized bifidobacteria suppressed fat accumulation and blood glucose level Biochem Biophys Res Commun 2018 501 1041 1047 29777696
24 Aoki R Kamikado K Suda W Takii H Mikami Y Suganuma N Hattori M Koga Y A proliferative probiotic Bifidobacterium strain in the gut ameliorates progression of metabolic disorders via microbiota modulation and acetate elevation Sci Rep 2017 7 43522 28252037
25 Yang JY Lee YS Kim Y Lee SH Ryu S Fukuda S Hase K Yang CS Lim HS Kim MS Kim HM Ahn SH Kwon BE Ko HJ Kweon MN Gut commensal Bacteroides acidifaciens prevents obesity and improves insulin sensitivity in mice Mucosal Immunol 2017 10 104 116 27118489
26 Wang J Tang H Zhang C Zhao Y Derrien M Rocher E van-Hylckama Vlieg JE Strissel K Zhao L Obin M Shen J Modulation of gut microbiota during probiotic-mediated attenuation of metabolic syndrome in high fat diet-fed mice ISME J 2015 9 1 15 24936764
27 Zhang X Shen D Fang Z Jie Z Qiu X Zhang C Chen Y Ji L Human gut microbiota changes reveal the progression of glucose intolerance PLoS One 2013 8 e71108 24013136
28 Okubo T Takemura N Yoshida A Sonoyama K KK/Ta Mice Administered Lactobacillus plantarum Strain No. 14 Have Lower Adiposity and Higher Insulin Sensitivity Biosci Microbiota Food Health 2013 32 93 100 24936367
29 Naito E Yoshida Y Makino K Kounoshi Y Kunihiro S Takahashi R Matsuzaki T Miyazaki K Ishikawa F Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice J Appl Microbiol 2011 110 650 657 21281408
30 Fåk F Bäckhed F Lactobacillus reuteri prevents diet-induced obesity, but not atherosclerosis, in a strain dependent fashion in Apoe-/- mice PLoS One 2012 7 e46837 23056479
31 Moroti C Souza Magri LF de Rezende Costa M Cavallini DC Sivieri K Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus Lipids Health Dis 2012 11 29 22356933
32 Kijmanawat A Panburana P Reutrakul S Tangshewinsirikul C Effects of probiotic supplements on insulin resistance in gestational diabetes mellitus: A double-blind randomized controlled trial J Diabetes Investig 2019 10 163 170
33 Tajabadi-Ebrahimi M Sharifi N Farrokhian A Raygan F Karamali F Razzaghi R Taheri S Asemi Z A Randomized Controlled Clinical Trial Investigating the Effect of Synbiotic Administration on Markers of Insulin Metabolism and Lipid Profiles in Overweight Type 2 Diabetic Patients with Coronary Heart Disease Exp Clin Endocrinol Diabetes 2017 125 21 27 27219886
34 Asemi Z Zare Z Shakeri H Sabihi SS Esmaillzadeh A Effect of multispecies probiotic supplements on metabolic profiles, hs-CRP, and oxidative stress in patients with type 2 diabetes Ann Nutr Metab 2013 63 1 9
35 Mofidi F Poustchi H Yari Z Nourinayyer B Merat S Sharafkhah M Malekzadeh R Hekmatdoost A Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial Br J Nutr 2017 117 662 668 28345499
36 Firouzi S Majid HA Ismail A Kamaruddin NA Barakatun-Nisak MY Effect of multi-strain probiotics (multi-strain microbial cell preparation) on glycemic control and other diabetes-related outcomes in people with type 2 diabetes: a randomized controlled trial Eur J Nutr 2017 56 1535 1550 26988693
37 Mohseni S Bayani M Bahmani F Tajabadi-Ebrahimi M Bayani MA Jafari P Asemi Z The beneficial effects of probiotic administration on wound healing and metabolic status in patients with diabetic foot ulcer: A randomized, double-blind, placebo-controlled trial Diabetes Metab Res Rev 2018 34
38 Gurung M Li Z You H Rodrigues R Jump DB Morgun A Shulzhenko N Role of gut microbiota in type 2 diabetes pathophysiology EBioMedicine 2020 51 102590 31901868
39 den Besten G Bleeker A Gerding A van Eunen K Havinga R van Dijk TH Oosterveer MH Jonker JW Groen AK Reijngoud DJ Bakker BM Short-Chain Fatty Acids Protect Against High-Fat Diet-Induced Obesity via a PPARγ-Dependent Switch From Lipogenesis to Fat Oxidation Diabetes 2015 64 2398 2408 25695945
40 Zhang L Qin Q Liu M Zhang X He F Wang G Akkermansia muciniphila can reduce the damage of gluco/lipotoxicity, oxidative stress and inflammation, and normalize intestine microbiota in streptozotocin-induced diabetic rats Pathog Dis 2018 76
41 Li X Wang N Yin B Fang D Jiang T Fang S Zhao J Zhang H Wang G Chen W Effects of Lactobacillus plantarum CCFM0236 on hyperglycaemia and insulin resistance in high-fat and streptozotocin-induced type 2 diabetic mice J Appl Microbiol 2016 121 1727 1736 27552342
42 Ojo O Feng QQ Ojo OO Wang XH The Role of Dietary Fibre in Modulating Gut Microbiota Dysbiosis in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials Nutrients 2020 12
43 Xi Y Xu PF Diabetes and gut microbiota World J Diabetes 2021 12 1693 1703 34754371
44 Gentile JKA Oliveira KD Pereira JG Tanaka DY Guidini GN Cadona MZ Siriani-Ribeiro DW Perondini MT THE INTESTINAL MICROBIOME IN PATIENTS UNDERGOING BARIATRIC SURGERY: A SYSTEMATIC REVIEW Arq Bras Cir Dig 2022 35 e1707 36542005
45 Ismail HM Evans-Molina C Does the Gut Microbiome Play a Role in Obesity in Type 1 Diabetes? Unanswered Questions and Review of the Literature Front Cell Infect Microbiol 2022 12 892291 35873174
46 Đanić M Pavlović N Stanimirov B Lazarević S Vukmirović S Al-Salami H Mikov M PAMPA model of gliclazide permeability: The impact of probiotic bacteria and bile acids Eur J Pharm Sci 2021 158 105668 33301903
47 van Bommel EJM Herrema H Davids M Kramer MHH Nieuwdorp M van Raalte DH Effects of 12-week treatment with dapagliflozin and gliclazide on faecal microbiome: Results of a double-blind randomized trial in patients with type 2 diabetes Diabetes Metab 2020 46 164 168 31816432
48 Zhang X Fang Z Zhang C Xia H Jie Z Han X Chen Y Ji L Effects of Acarbose on the Gut Microbiota of Prediabetic Patients: A Randomized, Double-blind, Controlled Crossover Trial Diabetes Ther 2017 8 293 307 28130771
49 Madsen MSA Holm JB Pallejà A Wismann P Fabricius K Rigbolt K Mikkelsen M Sommer M Jelsing J Nielsen HB Vrang N Hansen HH Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice Sci Rep 2019 9 15582 31666597
50 Zhang Q Xiao X Zheng J Li M Yu M Ping F Wang T Wang X Featured article: Structure moderation of gut microbiota in liraglutide-treated diabetic male rats Exp Biol Med (Maywood) 2018 243 34 44 29171288
51 Cefalo CMA Cinti F Moffa S Impronta F Sorice GP Mezza T Pontecorvi A Giaccari A Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives Cardiovasc Diabetol 2019 18 20 30819210
52 Singh RK Chang HW Yan D Lee KM Ucmak D Wong K Abrouk M Farahnik B Nakamura M Zhu TH Bhutani T Liao W Influence of diet on the gut microbiome and implications for human health J Transl Med 2017 15 73 28388917
53 Evans CC LePard KJ Kwak JW Stancukas MC Laskowski S Dougherty J Moulton L Glawe A Wang Y Leone V Antonopoulos DA Smith D Chang EB Ciancio MJ Exercise prevents weight gain and alters the gut microbiota in a mouse model of high fat diet-induced obesity PLoS One 2014 9 e92193 24670791
54 Kerry RG Patra JK Gouda S Park Y Shin HS Das G Benefaction of probiotics for human health: A review J Food Drug Anal 2018 26 927 939 29976412
55 Monda V Villano I Messina A Valenzano A Esposito T Moscatelli F Viggiano A Cibelli G Chieffi S Monda M Messina G Exercise Modifies the Gut Microbiota with Positive Health Effects Oxid Med Cell Longev 2017 2017 3831972 28357027
56 Aragón-Vela J Solis-Urra P Ruiz-Ojeda FJ Álvarez-Mercado AI Olivares-Arancibia J Plaza-Diaz J Impact of Exercise on Gut Microbiota in Obesity Nutrients 2021 13
57 Wegierska AE Charitos IA Topi S Potenza MA Montagnani M Santacroce L The Connection Between Physical Exercise and Gut Microbiota: Implications for Competitive Sports Athletes Sports Med 2022 52 2355 2369 35596883
58 Singh VP Sharma J Babu S RizwanullaSingla A Role of probiotics in health and disease: a review J Pak Med Assoc 2013 63 253 257 23894906
59 Tao YW Gu YL Mao XQ Zhang L Pei YF Effects of probiotics on type II diabetes mellitus: a meta-analysis J Transl Med 2020 18 30 31952517
60 Svensson CK Cold F Ribberholt I Zangenberg M Mirsepasi-Lauridsen HC Petersen AM Helms M The Efficacy of Faecal Microbiota Transplant and Rectal Bacteriotherapy in Patients with Recurrent Clostridioides difficile Infection: A Retrospective Cohort Study Cells 2022 11
61 Kobyliak N Falalyeyeva T Mykhalchyshyn G Kyriienko D Komissarenko I Effect of alive probiotic on insulin resistance in type 2 diabetes patients: Randomized clinical trial Diabetes Metab Syndr 2018 12 617 624 29661605
62 Kumari M Singh P Nataraj BH Kokkiligadda A Naithani H Azmal Ali S Behare PV Nagpal R Fostering next-generation probiotics in human gut by targeted dietary modulation: An emerging perspective Food Res Int 2021 150 110716 34865747
63 Zhao D Zhu H Gao F Qian Z Mao W Yin Y Tan J Chen D Antidiabetic effects of selenium-enriched Bifidobacterium longum DD98 in type 2 diabetes model of mice Food Funct 2020 11 6528 6541 32638790
64 Palacios T Vitetta L Coulson S Madigan CD Lam YY Manuel R Briskey D Hendy C Kim JN Ishoey T Soto-Giron MJ Schott EM Toledo G Caterson ID Targeting the Intestinal Microbiota to Prevent Type 2 Diabetes and Enhance the Effect of Metformin on Glycaemia: A Randomised Controlled Pilot Study Nutrients 2020 12
65 Razmpoosh E Javadi A Ejtahed HS Mirmiran P Javadi M Yousefinejad A The effect of probiotic supplementation on glycemic control and lipid profile in patients with type 2 diabetes: A randomized placebo controlled trial Diabetes Metab Syndr 2019 13 175 182 30641692
66 Madempudi RS Ahire JJ Neelamraju J Tripathi A Nanal S Efficacy of UB0316, a multi-strain probiotic formulation in patients with type 2 diabetes mellitus: A double blind, randomized, placebo controlled study PLoS One 2019 14 e0225168 31721790
67 Sabico S Al-Mashharawi A Al-Daghri NM Wani K Amer OE Hussain DS Ahmed Ansari MG Masoud MS Alokail MS McTernan PG Effects of a 6-month multi-strain probiotics supplementation in endotoxemic, inflammatory and cardiometabolic status of T2DM patients: A randomized, double-blind, placebo-controlled trial Clin Nutr 2019 38 1561 1569 30170781
68 Mazruei Arani N Emam-Djomeh Z Tavakolipour H Sharafati-Chaleshtori R Soleimani A Asemi Z The Effects of Probiotic Honey Consumption on Metabolic Status in Patients with Diabetic Nephropathy: a Randomized, Double-Blind, Controlled Trial Probiotics Antimicrob Proteins 2019 11 1195 1201 30218286
69 Kassaian N Feizi A Aminorroaya A Jafari P Ebrahimi MT Amini M The effects of probiotics and synbiotic supplementation on glucose and insulin metabolism in adults with prediabetes: a double-blind randomized clinical trial Acta Diabetol 2018 55 1019 1028 29931423
70 Ebrahimi ZS Nasli-Esfahani E Nadjarzade A Mozaffari-Khosravi H Effect of symbiotic supplementation on glycemic control, lipid profiles and microalbuminuria in patients with non-obese type 2 diabetes: a randomized, double-blind, clinical trial J Diabetes Metab Disord 2017 16 23 28589103
71 Asemi Z Alizadeh SA Ahmad K Goli M Esmaillzadeh A Effects of beta-carotene fortified synbiotic food on metabolic control of patients with type 2 diabetes mellitus: A double-blind randomized cross-over controlled clinical trial Clin Nutr 2016 35 819 825 26209256
72 Madjd A Taylor MA Mousavi N Delavari A Malekzadeh R Macdonald IA Farshchi HR Comparison of the effect of daily consumption of probiotic compared with low-fat conventional yogurt on weight loss in healthy obese women following an energy-restricted diet: a randomized controlled trial Am J Clin Nutr 2016 103 323 329 26702123
73 Karamali M Dadkhah F Sadrkhanlou M Jamilian M Ahmadi S Tajabadi-Ebrahimi M Jafari P Asemi Z Effects of probiotic supplementation on glycaemic control and lipid profiles in gestational diabetes: A randomized, double-blind, placebo-controlled trial Diabetes Metab 2016 42 234 241 27209439
74 Ostadrahimi A Taghizadeh A Mobasseri M Farrin N Payahoo L Beyramalipoor Gheshlaghi Z Vahedjabbari M Effect of probiotic fermented milk (kefir) on glycemic control and lipid profile in type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial Iran J Public Health 2015 44 228 237 25905057
75 Eslamparast T Poustchi H Zamani F Sharafkhah M Malekzadeh R Hekmatdoost A Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study Am J Clin Nutr 2014 99 535 542 24401715
76 Rajkumar H Mahmood N Kumar M Varikuti SR Challa HR Myakala SP Effect of probiotic (VSL#3) and omega-3 on lipid profile, insulin sensitivity, inflammatory markers, and gut colonization in overweight adults: a randomized, controlled trial Mediators Inflamm 2014 2014 348959 24795503
77 Ivey KL Hodgson JM Kerr DA Lewis JR Thompson PL Prince RL The effects of probiotic bacteria on glycaemic control in overweight men and women: a randomised controlled trial Eur J Clin Nutr 2014 68 447 452 24569536
78 Mohamadshahi M Veissi M Haidari F Shahbazian H Kaydani GA Mohammadi F Effects of probiotic yogurt consumption on inflammatory biomarkers in patients with type 2 diabetes Bioimpacts 2014 4 83 88 25035851
79 Asemi Z Khorrami-Rad A Alizadeh SA Shakeri H Esmaillzadeh A Effects of synbiotic food consumption on metabolic status of diabetic patients: a double-blind randomized cross-over controlled clinical trial Clin Nutr 2014 33 198 203 23786900
80 Mazloom Z Yousefinejad A Dabbaghmanesh MH Effect of probiotics on lipid profile, glycemic control, insulin action, oxidative stress, and inflammatory markers in patients with type 2 diabetes: a clinical trial Iran J Med Sci 2013 38 38 43 23645956
81 Shavakhi A Minakari M Firouzian H Assali R Hekmatdoost A Ferns G Effect of a Probiotic and Metformin on Liver Aminotransferases in Non-alcoholic Steatohepatitis: A Double Blind Randomized Clinical Trial Int J Prev Med 2013 4 531 537 23930163
82 Asemi Z Samimi M Tabassi Z Naghibi Rad M Rahimi Foroushani A Khorammian H Esmaillzadeh A Effect of daily consumption of probiotic yoghurt on insulin resistance in pregnant women: a randomized controlled trial Eur J Clin Nutr 2013 67 71 74 23187955
83 Ejtahed HS Mohtadi-Nia J Homayouni-Rad A Niafar M Asghari-Jafarabadi M Mofid V Probiotic yogurt improves antioxidant status in type 2 diabetic patients Nutrition 2012 28 539 543 22129852
84 Laitinen K Poussa T Isolauri E Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota Group Probiotics and dietary counselling contribute to glucose regulation during and after pregnancy: a randomised controlled trial Br J Nutr 2009 101 1679 1687 19017418
